LSE company dividends information has been updated. You can find this is in the menu on any Quote page. ADVFN team.


Nuformix Plc

0.025 (11.36%)
Share Name Share Symbol Market Type Share ISIN Share Description
Nuformix Plc LSE:NFX London Ordinary Share GB00BYW79Y38 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.025 11.36% 0.245 3,323,200 16:35:16
Bid Price Offer Price High Price Low Price Open Price
0.22 0.27 0.25 0.25 0.25
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceutical Preparations 0.05 -1.11 -0.20 - 1.74
Last Trade Time Trade Type Trade Size Trade Price Currency
14:36:32 O 1,639 0.22 GBX

Nuformix (NFX) Latest News

Nuformix (NFX) Discussions and Chat

Nuformix Forums and Chat

Date Time Title Posts
01/6/202312:50NUFORMIX September 2 Presentations - Massive Upside NFX157
18/5/202307:08Nuformix plc9,116

Add a New Thread

Nuformix (NFX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type

Nuformix (NFX) Top Chat Posts

Top Posts
Posted at 18/5/2023 10:49 by institutional investments
Price a good sign

Tomorrow is the big day

Kept down today for funds to get in

Thursday/Friday be spectacular

Posted at 18/5/2023 10:46 by dogsoggy36
100% it was not leaked,Never saw any results at all.Feel free to take a trip to the chat and see for yourself.Why has the price not moved is because Lanstead keep selling and 10% traders killed the momentum.
Posted at 17/4/2023 21:52 by vaston
Watch the mms have fun playing with the price tomorrow.
Posted at 17/4/2023 08:07 by supercity
Hilarious here - a 70k fund raise which is obviously to give a mate a stake in the company (the shares won't be sold) and the MMs drop the price.Don't knock a gift horse but the drop is total nonsense from sellers who have only read the headline - back level or positive within a few days or by the end of the day - mark my words
Posted at 27/3/2023 07:29 by manual dexterity
Nuformix PLC NXP002 Update
27/03/2023 7:00am
UK Regulatory (RNS & others)

Nuformix (LSE:NFX)
Intraday Stock Chart

Monday 27 March 2023

Click Here for more Nuformix Charts.

RNS Number : 2322U

Nuformix PLC

27 March 2023

27 March 2023

Nuformix plc

("Nuformix" or the "Company" or the "Group")

NXP002 Update

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce the following update regarding the Company's NXP002 programme, a proprietary new form of tranilast, being developed as a novel inhaled treatment for Idiopathic Pulmonary Fibrosis ("IPF").

The Company recently announced the commencement of studies using a new iteration of a 3D human IPF lung tissue model - a high-challenge, disease and species relevant pre-clinical model with its partner, Fibrofind. Advancements within this model were designed to significantly reduce output variability. The Company has now received results from these studies of NXP002 alone and in combination with current standards of care ("SoC"), and they can be summarised as follows:

-- NXP002 is well tolerated in ex-vivo human lung tissue with no signs of toxicity events;
-- NXP002 alone delivers a strong, consistent anti-fibrotic effect as demonstrated by modulation of the release of multiple biomarkers of fibrosis;

-- Both high and low concentrations of NXP002 show an additive anti-fibrotic effect to SoC;
-- In particular, the higher concentrations of NXP002 with SoC's deliver a near complete ablation of fibrosis biomarker release, yet at lower concentrations than have been seen in other pre-clinical models to date; and

-- The clear, pronounced additive benefit of NXP002 on top of SoCs observed suggests that NXP002 will provide additional efficacy, even in patients responding to SoC therapy. This raises the possibility that NXP002 targets additional disease pathways to SoC's when increasing the combined anti-fibrotic response.

Overall, the results provide further support of NXP002's potential to increase efficacy of existing therapies with the benefits of inhaled delivery (e.g. added efficacy without increased side effects). They also support NXP002's potential as a monotherapy for patients declining SoCs - a meaningful proportion of IPF patients who choose against the side effects of SoCs, which impact quality of life.

Following the success achieved in these studies the Company's next steps include:

-- Investigation of inflammation-related biomarkers in the same tissue sample sets to confirm additional mechanistic and anti-inflammatory benefits on top of SoC's, given the positive anti-fibrotic response;

-- Expansion of the current study to include tissue from an additional two further human IPF tissue donors to demonstrate the robustness of NXP002's anti-fibrotic response alone and in SoC combinations in multiple patients; and

-- To consider the expansion of the Company's on-going healthy lung tissue study investigating NXP002's duration of action to three donors, based on results when received.

Understanding the performance of new IPF therapies with SoC's has become critical to both potential development partners and regulators. Therefore, the Company believes completion of these steps is required for Nuformix to secure the interest of out-licensing partners.

Results will continue to be generated with further updates announced when appropriate .

Commenting, Dr Dan Gooding, Executive Director of Nuformix, said: " All parties are delighted with the results from this study, which are as good as we could have hoped for and are the first results from what is the most advanced iteration of this 'close to patient' IPF disease model to date. The reduced variability in the resulting data allows us to have high confidence in both NXP002's anti-fibrotic activity alone, but also in the added anti-fibrotic performance it can deliver on top of existing standards of care. Additivity to standard of care is the most important aspect because it's the simplest option to investigate in a clinical study and is therefore fast becoming a top priority for potential licensing partners. Having seen the quality of these results, our aim now is to generate datasets from three donors in both human IPF and healthy lung duration of action studies. These data can be generated quickly and will be essential in opening up new discussions with potential licensing partners and support overall progression of the NXP002 programme."


Nuformix plc
Dr Dan Gooding, Executive Director Via IFC Advisory
Stanford Capital Partners Limited
Tom Price / Patrick Claridge (Corporate
Finance) +44 (0) 20 3650 3650
John Howes (Corporate Broking) +44 (0) 20 3650 3652
IFC Advisory Limited
Tim Metcalfe +44 (0) 20 3934 6630
Zach Cohen

Posted at 20/6/2022 16:55 by pwhite73
The first sentence proves my very point.

"The payment for the shares (£1.65m gross less legal fees) is paid to Nuformix but pledged to Lanstead"

So the proceeds from the subscription is physically and financially paid to Nuformix. Nuformix then only "pledge" the money back to Lanstead depending on the share price. There is no shortfall in funds for Nuformix.

If the share price is only 0.27p and the placing price was 1.5p it means NFX will only receive £300k of the £1.65m proceeds assuming the price does not drop further if Lanstead were holding the cash from the placings.

As I said these RNSes are designed to trick you into thinking the death spiral funder has an interest in the progress of company. Its also important to note no further shares will be issued to make up for any shortfall in the share price.

Posted at 20/6/2022 15:53 by soupdragon55
Pwhite, its a subscription with Lanstead based on the 1.5p shareprice. The £1.65m from this does not sit in NFX bank account. It sits in ESCROW, with an agreement that Lanstead release it each month.

So if the share price is 50% lower than the benchmark, NFX only get a 50% payment that month. The rest goes back to Lanstead. Therefore Lanstead have paid less than the 1.5p benchmark.

So if Lanstead dump all of their shares now and the price drops. They still have to pay each month, but will be paying a lot less and claiming back the difference.

Therefore that would be market manipulation. So they can only sell stock they have paid NFX for.

Posted at 20/12/2021 19:24 by sentiment riles
Good morning,

The Board is confident, following recent preclinical data in NXP002 and the strengthening of its IP portfolio around NXP004, that the near-term prospects for these products are strong, and will be further enhanced by additional pre-clinical development, including formulation work, toxicology studies, and preparations for Phase I trials, in addition to parallel business development work with potential partners.

As the business strategy is executed, the Company is confident that this will be reflected by an increase in the share price, which will both increase the amount of money received by Nuformix in the Lanstead subscription, but also benefit Lanstead as the value of its investment will be higher. It is important to reiterate that Lanstead does not benefit from the share price declining, and they certainly do not ‘have control of the share price’ as you stated below – I am not sure what you mean when you refer to March 2020. As with any shareholder, Lanstead benefits when the share price appreciates.

The Company spoke at length with Lanstead ahead of the subscription, and also spoke with executives from some of its other portfolio companies, which further underlined that Lanstead will be a supportive, long-term shareholder that has confidence in the Company’s ability to create value.

If you have any further questions regarding the placing, there is a Q&A available on the Nuformix website:[...]

Posted at 14/12/2021 17:53 by sentiment riles
Lanstead Investment – Q&A
Q. Why did Nuformix choose the Sharing Agreements with Lanstead?
A: The sharing agreements with Lanstead allows Nuformix to benefit from positive share price
performance over 20 months and the funding supports Nuformix’s activities over that period. We
see a number of positive catalysts for Nuformix over the coming months, in particular as we make
NXP004 Phase 1 ready and continue to strengthen the IP around NXP004, which should be
positive for the share price as these are announced.
Q: Is Lanstead entitled to invest monthly at a fixed discount to the prevailing Nuformix
share price from month-to-month?
A: No. Lanstead will be issued and will immediately pay for the shares it subscribes for at 1.5p
per share. The number of shares issued to Lanstead is fixed and does not change. However, the
amount from Lanstead due to the Company under the sharing agreements is adjustable upwards
or downwards at each of the 20 monthly settlements that follow. For example; the approximate
amount in any particular month will be 10% more than £82,500 if the share price is 10% higher
than the 2.0p benchmark price (“BMP”) or 10% less than £82,500 if the share price is 10% lower
than the BMP.
Q: Can Lanstead benefit by the share price being lower than the 2.0p BMP, rather than
going higher than 2.0p?
A: No. Lanstead makes more money the higher the share price is. Through the sharing
agreements Lanstead shares some, but not all, of the upside when the share price appreciates
with Nuformix. The sharing agreements are an incentive for Nuformix to perform, thereby
benefitting all shareholders including Lanstead.
If the share price over 20 months averages double the BMP (i.e. 4.0p) then the Company will
receive double the initial Lanstead subscription of £1.65 million (i.e. £3.30 million instead of £1.65
million). If the share price over 20 months averages half the BMP (i.e. 1.0p) then the Company
will ultimately receive half the initial Lanstead subscription (i.e. £0.825 million instead of £1.65
The projected outcome for Nuformix is contractually clear and the value of Lanstead’s
investment is greater if the company’s share price is higher.
It is important to note that Lanstead participates in the majority, but not all of the upside in any
future Nuformix share price appreciation. The bottom line is that Lanstead makes more money as
the share price rises and does not derive any advantage from a decline in the share price.
Q: Can Lanstead trade its Nuformix shares?
A: Lanstead has a demonstrable track record of being a longer-term supportive shareholder to its
investee companies. Like any institutional investor Lanstead only invests in companies where it
can see strong potential for share price appreciation.
Lanstead is free to buy and sell shares just like any other shareholder and it is required to disclose
movements of >1% as a significant disclosable shareholder. Unlike other shareholders, Lanstead
has an uncapped commitment through the sharing agreements to remit amounts each month to
Nuformix based on the prevailing share price. Therefore whilst Lanstead may take a profit along
the way (like any shareholder) and cover its downside risk on the investment (just like any
shareholder), Lanstead also has an incentive (unlike other shareholders) to maintain a significant
on-going shareholding because of its uncapped exposure on the amounts due to Nuformix over
the 20 months of the sharing agreements should the Nuformix shares appreciate

Posted at 21/10/2021 11:32 by inipvestor
Nuformix PLC (LON: NFX) share price surged 12.7% despite the pharmaceutical company not making significant announcements today. Here's why.The lack of news from the company indicates that today's move higher was primarily driven by buying pressure from investors and positive sentiment. The last significant announcement from Nuformix was in September when it signed an exclusive licensing deal with Oxilio Ltd to develop and commercialise its cancer drug.While there is no direct trigger behind today's rally, we know that the one single driver behind a rallying share price is buying pressure.Therefore, we can confidently say that a wave of buying pressure has hit Nuformix share, triggering the rally.The buying pressure could be from a single institutional investor accumulating a significant position in the pharma company, or it could be from a group of investors with a bullish view of the stock.From a technical analysis standpoint, Nuformix shares have pushed back above the crucial 1.30p resistance level that could now act as support.However, we would need to see further gains before saying that the resistance level has turned into support. Currently, we could see the price fail to hold above the level leading to a further decline.Investors interested in opening new bullish positions in the stock should wait for the price to hold above the support zone and retest it before jumping in.People Who Read This Also ReadSensyne Health Share Price Trades Sideways Despite EU Regulatory ApprovalCeres Power Share Price Edged Higher After Appointing a New CFOPhoenix Copper Share Price Climbs As ADR's to Begin US Tr
Nuformix share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |

V: D: 20230605 17:53:26